The Biden administration has reached an agreement with drugmakers to lower prices on the 10 costliest prescription drugs under Medicare. The negotiated prices for these drugs, including blood thinners, diabetes medications, and arthritis drugs, have been significantly reduced from their list prices. These lower prices are expected to save Medicare enrollees $1.5 billion in out-of-pocket costs in the first year. The negotiations, mandated under the Inflation Reduction Act, are part of the federal government’s efforts to address the high cost of prescription drugs and reduce the financial burden on older adults in the U.S.
The agreement marks the first time the federal government has directly negotiated drug prices with manufacturers. The negotiations are planned to expand to include more drugs in the coming years, potentially saving seniors even more money on prescription medications. While the drug industry has raised concerns about the negotiations, the administration views the agreement as a significant step towards lowering healthcare costs for Medicare beneficiaries.
The new negotiated prices will not take effect until 2026, but they are estimated to save Medicare $6 billion in the first year alone. The administration plans to leverage these negotiations to promote Vice President Kamala Harris’ campaign ahead of the presidential election. The high cost of prescription drugs has been a major concern for older adults in the U.S., with many struggling to afford necessary medications. The agreement with drugmakers represents a significant milestone in the government’s efforts to address this issue and improve access to affordable healthcare for Medicare beneficiaries.
Photo credit
www.nbcnews.com